The prognostic role of next-generation imaging-driven upstaging in newly diagnosed prostate cancer patients.
Matteo BaucknehtEnrico CheccucciEdoardo CiseroAlessio RizzoManuela RaccaSabrina De CillisDaniele AmparoreStefano De LucaCristian FioriPasquale RescignoFrancesco PorpigliaPublished in: European journal of nuclear medicine and molecular imaging (2023)
In conclusion, implementing NGI for staging purposes improves the prediction of bRFS. Although phase III evidence is still needed, this advancement suggests that NGI may better identify patients who would benefit from local treatments than those who may achieve better oncological outcomes through systemic treatment.
Keyphrases
- phase iii
- newly diagnosed
- open label
- prostate cancer
- clinical trial
- high resolution
- lymph node
- phase ii
- double blind
- rectal cancer
- radical prostatectomy
- placebo controlled
- randomized controlled trial
- quality improvement
- metabolic syndrome
- benign prostatic hyperplasia
- robot assisted
- skeletal muscle
- photodynamic therapy
- study protocol
- drug induced
- glycemic control